Results 11 to 20 of about 589,763 (321)

COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease

Infection and Drug Resistance, 2020
Amin Sadeghi Dousari,1 Majid Taati Moghadam,2,3 Naghmeh Satarzadeh4,5 1Department of Microbiology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran; 2Department of Microbiology, School of Medicine, Iran University of Medical ...
Sadeghi Dousari A, Taati Moghadam M, Satarzadeh N   +2 more
doaj   +3 more sources

Otorhinolaryngologists and Coronavirus Disease 2019 (COVID-19) [PDF]

International Archives of Otorhinolaryngology, 2020
Geraldo Pereira Jotz, Richard Louis Voegels, Ricardo Ferreira Bento   +2 more
doaj   +4 more sources

Resolution of coronavirus disease 2019 (COVID-19) [PDF]

Expert Review of Anti-infective Therapy, 2020
Coronavirus disease 2019 (COVID-19) was first detected in China in December, 2019, and declared as a pandemic by the World Health Organization (WHO) on March 11, 2020. The current management of COVID-19 is based generally on supportive therapy and treatment to prevent respiratory failure.
Habas, Khaled, Nganwuchu, Chioma, Shahzad, Fanila, Gopalan, Rajendran, Haque, Mainul, Rahman, Sayeeda, Majumder, Anwarul Azim, Nasim, Talat   +7 more
openaire   +3 more sources

Update on Coronavirus Disease 2019 (COVID-19) [PDF]

The Open Neurology Journal, 2020
n ...
Teresa A Santantonio, Teresa A Santantonio, Giovanni Messina   +2 more
openaire   +4 more sources

Coronavirus Disease 2019 (COVID–19): A Short Review on Hematological Manifestations

Pathogens, 2020
Infection with severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) is a rapidly spreading and devastating global pandemic. Many researchers are attempting to clarify the mechanisms of infection and to develop a drug or vaccine against the virus,
Artur Słomka, Mariusz Kowalewski, Ewa Żekanowska   +2 more
doaj   +1 more source

Bacterial coinfections with coronavirus disease 2019 (COVID-19) [PDF]

Antimicrobial Stewardship & Healthcare Epidemiology, 2021
Abstract Background: The pandemic caused by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) has dramatically increased cheshospitalizations, and it is often difficult to determine whether there is a bacterial or fungal coinfection at time of presentation.
Glen Huang, Daisuke Furukawa, Bryant D. Yang, Brian J. Kim, Arthur C. Jeng   +4 more
openaire   +3 more sources

Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

Exploration, 2022
Coronavirus disease 2019 (COVID‐19) continually poses a significant threat to the human race, and prophylactic vaccination is the most potent approach to end this pandemic.
Ziqi Wang, Kai Cui, Ulrich Costabel, Xiaoju Zhang   +3 more
doaj   +1 more source

Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]

, 2020
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core   +1 more source

Parotitis as clinical manifestation of COVID-19 infection, emergency physician experience: A case report

Medicine Science, 2020
COVID-19 (coronavirus disease 2019) is a viral infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a World Health Organization (WHO) declared pandemic.
Monira Taha Ismail, Mahmoud Mohamed Naser   +1 more
doaj   +1 more source

A brief overview of current drug repurposing approaches for COVID-19 management [PDF]

, 2020
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares, Thomaz, Douglas Vieira   +1 more
core   +2 more sources